What is Joint Academy?
Joint Academy, developed by Arthro, operates at the intersection of clinical research and digital therapeutics. The platform provides a scientifically validated treatment program for osteoarthritis, meticulously designed in collaboration with orthopedic specialists, researchers, and physiotherapists. Unlike conventional wellness applications, Joint Academy adheres to stringent healthcare regulations, ensuring that patient health journals and personal data are managed with the same rigor as traditional medical institutions. The company's commitment to peer-reviewed research and adherence to international clinical guidelines distinguishes it as a leader in the digital musculoskeletal health space, offering a long-term, sustainable alternative to surgical interventions and pharmaceutical reliance.
How much funding has Joint Academy raised?
Joint Academy has raised a total of $30M across 2 funding rounds:
Series A
$7M
Series B
$23M
Series A (2018): $7M, investors not publicly disclosed
Series B (2020): $23M led by Kinnevik
Key Investors in Joint Academy
Kinnevik
Kinnevik is an industry-focused investment firm with a long history of building digital consumer businesses through partnerships with talented founders.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Joint Academy?
With the successful closure of its latest funding round, Joint Academy is well-positioned to scale its operations and expand its clinical footprint. The strategic deployment of this capital will likely focus on enhancing the platform's technological infrastructure, broadening its reach into new international markets, and deepening its integration with existing healthcare systems. As the demand for remote, high-quality chronic care continues to rise, Joint Academy's focus on data-driven outcomes and regulatory compliance provides a competitive moat. Future initiatives will likely involve further clinical studies to solidify its efficacy claims and potential partnerships with insurance providers to facilitate broader patient access to its digital treatment protocols.
See full Joint Academy company page
